B of A Securities Initiates Coverage On Reneo Pharmaceuticals with Buy Rating, Announces Price Target of $23
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Jason Zemansky has initiated coverage on Reneo Pharmaceuticals (NASDAQ:RPHM) with a Buy rating and a price target of $23.
July 03, 2023 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reneo Pharmaceuticals has been initiated with a Buy rating by B of A Securities, with a price target of $23.
The initiation of coverage by B of A Securities with a Buy rating and a price target of $23 indicates a positive outlook for Reneo Pharmaceuticals. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100